IL-15 Agonist and Antibiotic Combination for Surgical Infection Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics, such as cephalosporins, used to prevent surgical site infections can suppress immune responses, including those mediated by IL-15, which is critical for innate and adaptive immune responses, necessitating a need for improved compositions and methods that stimulate the immune system without compromising infection prevention or treatment.
Innovation Solution
The use of an IL-15 agonist, specifically nogapendekin alfa-inbakicept (NAI), in combination with antibiotics like cefazolin, administered before or after surgical procedures to enhance immune response and prevent or treat infections without suppressing cytokine activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics such as cephalosporins are administered to prevent surgical site infections, then infection prevention is improved, but immune response is suppressed
Solution Approach 1:
The patent divides the therapeutic approach into two separate components: an antibiotic (cephalosporin) for infection prevention and an IL-15 agonist for immune stimulation. This segmentation allows each component to perform its specific function independently, with the antibiotic maintaining antimicrobial efficacy while the IL-15 agonist counteracts immune suppression without interfering with the antibiotic's primary action.
Solution Approach 2:
The IL-15 agonist acts as an intermediary substance that mediates between the antibiotic's immune-suppressing effect and the need for immune response. By introducing this intermediate agent, the patent enables the antibiotic to continue its infection-preventing function while the IL-15 agonist compensates for the harmful immune suppression through cytokine stimulation.
2Object-affected harmful factors
If IL-15 agonist is administered to stimulate immune response, then immune response is enhanced, but infection prevention may be compromised without antibiotic coverage
Solution Approach 1:
The patent merges two therapeutic approaches into a single combination treatment: antibiotic therapy for infection prevention and IL-15 agonist therapy for immune stimulation. This combination ensures that both infection prevention and immune response enhancement are achieved simultaneously, with the antibiotic providing reliable infection prevention while the IL-15 agonist enhances immune response without compromising the antibiotic's protective effect.
3Reliability
If conventional antibiotic therapy is used alone, then infection prevention is maintained, but immune-mediated protection is reduced
Solution Approach 1:
The patent applies preliminary action by administering the IL-15 agonist in conjunction with the antibiotic to pre-stimulate the immune system before potential infections can exploit the antibiotic-induced immune suppression. This preliminary immune stimulation ensures that immune-mediated protection is enhanced in advance, allowing the immune system to be more responsive to potential pathogens while the antibiotic maintains its infection-preventing function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of IL-15 agonists with antibiotics effectively stimulates the immune system, preventing or reducing the occurrence of infections post-surgically while maintaining the antimicrobial efficacy of the antibiotics, thereby addressing the immune suppression issue.
Implementation Method 1
Binding of IL-15 to IL-15Rα activates the intracellular JAK/STAT signaling pathway, leading to systemic immunomodulatory effects.
Data Source
AI summary
Methods and pharmaceutical combinations for preventing, reducing the occurrence of, and/or treating an infection in a subject are provided herein. The method includes administering to the subject a therapeutically effective amount of an IL-15 agonist after or concomitantly with administration of a therapeutically effective amount of an antibiotic to the subject. The pharmaceutical combination includes an IL-15 agonist and an antibiotic.